NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/05/2026 10:42
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,202.88 mln
Float84.99 mln
Earnings Date05/20/2026
Piotroski F-Score
5
/ 9
Neutral
1-Year Forecast
38.40
Exceptional upside
Relative Strength
69
/ 100
Outperforming
Debt / Equity
0.12
Very low leverage
ROE
-76.05
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Alumis Inc. is a drug development company based in South San Francisco, California, working to bring new treatments to patients with autoimmune and inflammatory conditions. Its leading drug candidate targets a protein called TYK2, which plays a key role in driving diseases such as plaque psoriasis and lupus, while a second compound in early-stage testing aims to address inflammation in the brain and nervous system. The company is also developing treatments for thyroid eye disease and broader immune system disorders. Founded in 2021 under the name Esker Therapeutics, Alumis is working to build a focused portfolio of medicines in areas where patients still have limited options.
